Physiomics hires Head of Business Development
31 August 2021
Physiomics plc
("Physiomics") or ("the Company")
Physiomics hires Head of Business Development
Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that Hayley Close has today joined the Company as Head of Business Development.
Hayley holds a degree in Biomedical Science from University College London and joins us from Fusion Antibodies plc where she was Key Account Manager responsible for identifying and engaging with new clients and developing existing business globally. At Physiomics, Hayley will work directly with the CEO and senior management team with the aim of significantly expanding both existing and new business.
Dr Jim Millen, CEO, commented "Physiomics has reached the stage of its growth where we believe there will be real benefit in retaining a full-time business development executive. Hailey joins us with a fantastic track-record and we look forward to working with her to significantly expand Physiomics' business".
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 80 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 15 minutes ago Alphawave IP Group
- 1 hour ago WH Smith
- 1 hour ago Staffline Group
- 1 hour ago Manchester & London Investment Trust
- 2 hours ago Associated British Foods